Abstract | PURPOSE: PATIENTS AND METHODS: We enrolled 61 patients with breast cancer, belonging to 4 subgroups, according to molecular phenotypes: 24 triple-negative/basal-like, 13 HER2-like, 20 luminal B, and 4 luminal A. All patients underwent weekly chemotherapy with carboplatin AUC2, paclitaxel 80 mg/m2, with trastuzumab (in case of HER2 positivity) 2 mg/kg, except for luminal A patients, who underwent only hormonal therapy. Among 61 patients, 26 (43%) received modified radical mastectomy and 35 (57%) received breast-conserving surgery. RESULTS: The patients obtaining pathologic complete response (pCR) were 20 (83%) of 24 triple-negative/basal-like, 10 (76%) of 13 HER2-like, 6 (30%) of 20 luminal B, and 3 (75%) of 4 luminal A. All the patients were evaluated for toxicity: no grade 4 was detected, 5 patients experienced grade 3 neuropathy, then reverted to G2 after chemotherapy discontinuation. At a minimum follow-up of 5 years, median overall survival was 48 months. CONCLUSION:
|
Authors | Francesca De Iuliis, Gerardo Salerno, Raffaella Corvino, Debora D'Aniello, Katia Cefalì, Ludovica Taglieri, Rosina Lanza, Susanna Scarpa |
Journal | Clinical breast cancer
(Clin Breast Cancer)
Vol. 17
Issue 1
Pg. 34-40
(02 2017)
ISSN: 1938-0666 [Electronic] United States |
PMID | 27435626
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright © 2016 Elsevier Inc. All rights reserved. |
Chemical References |
- Anthracyclines
- Carboplatin
- Trastuzumab
- Paclitaxel
|
Topics |
- Anthracyclines
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Carboplatin
(administration & dosage)
- Case-Control Studies
- Chemotherapy, Adjuvant
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Paclitaxel
(administration & dosage)
- Prognosis
- Prospective Studies
- Survival Rate
- Trastuzumab
(administration & dosage)
|